Focus Partners Wealth Has $113.53 Million Position in Amgen Inc. $AMGN

Key Points

• Focus Partners Wealth increased its Amgen stake by 60.7% in the fourth quarter, ending with 366,355 shares valued at about $113.5 million.
• Amgen reported better-than-expected quarterly results, with EPS of $5.15 versus $4.77 expected and revenue of $8.62 billion, while also reaffirming FY 2026 EPS guidance of 21.7 to 23.1.
• Investor attention remains split between bullish pipeline news and a key regulatory risk: Amgen is advancing trials for ABP 938 and MARITIME-SWITCH, but Tavneos faces a proposed FDA withdrawal that could pressure sentiment.

Focus Partners Wealth lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 60.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 366,355 shares of the medical research company's stock after purchasing an additional 138,334 shares during the period. Focus Partners Wealth owned 0.07% of Amgen worth $113,525,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. raised its position in shares of Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company's stock valued at $157,584,000 after purchasing an additional 43,884 shares during the period. Curtis Advisory Group LLC bought a new stake in shares of Amgen during the 4th quarter worth about $1,669,000. Adell Harriman & Carpenter Inc. boosted its holdings in shares of Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company's stock worth $7,204,000 after buying an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Amgen in the 4th quarter valued at about $22,441,000. Finally, Sigma Planning Corp grew its stake in Amgen by 24.0% in the 4th quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company's stock valued at $5,889,000 after buying an additional 3,488 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

NASDAQ AMGN opened at $355.20 on Monday. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company has a market capitalization of $191.70 billion, a P/E ratio of 24.72, a P/E/G ratio of 3.56 and a beta of 0.42. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The firm has a 50-day moving average price of $340.97 and a two-hundred day moving average price of $345.80.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Royal Bank Of Canada upped their price target on shares of Amgen from $360.00 to $370.00 and gave the company an "outperform" rating in a research note on Tuesday, April 7th. Guggenheim decreased their price target on shares of Amgen from $351.00 to $340.00 and set a "neutral" rating on the stock in a research note on Monday, May 4th. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a research note on Friday, June 5th. Wells Fargo & Company upped their price target on shares of Amgen from $375.00 to $390.00 and gave the company an "equal weight" rating in a research note on Thursday, March 19th. Finally, UBS Group upped their price target on shares of Amgen from $390.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $354.12.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company's stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.85% of the stock is owned by corporate insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.